CoChat
Sign Up
Cited by 44Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryCaveolin-1 and cellular processes

Recent Advances on Extracellular Vesicles in Central Nervous System Diseases

Open access
Jin, Tao, Gu, Jiachen, Li, Zongshan, Xu, Zhongping, Gui, Yaxing·2021·Clinical Interventions in Aging
DOI 10.2147/cia.s288415PMC PMC7882422
Open this paper in CoChat — free accountOpen PDF

Abstract

Extracellular vesicles (EVs) are particles released by multiple cells, encapsulated by lipid bilayers and containing a variety of biological materials, including proteins, nucleic acids, lipids and metabolites. With the advancement of separation and characterization methods, EV subtypes and their complex and diverse functions have been recognized. In the central nervous system (CNS), EVs are involved in various physiological and pathological processes, such as regulation of neuronal firing, synaptic plasticity, formation and maintenance of myelin sheath, propagation of neuroinflammation, neuroprotection, and spread and removal of toxic protein aggregates. Activity-dependent alteration of constituents enables EVs to reflect the change of cell and tissue states, and the wide distribution of EVs in biological fluids endows them with potential as diagnostic and prognostic biomarkers for CNS diseases, including neurodegenerative disease, cerebrovascular disease, traumatic brain disease, and brain tumor. Favorable biocompatibility, ability of crossing the blood-brain barrier and protecting contents from degradation, give promising therapeutic effects of EVs, either collected from mesenchymal stem cells culture conditioned media, or designed as drug delivery vehicles loaded with specific agents. In this review, we summarized EVs' basic biological properties, and mainly focused on their applications in CNS diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/cia.s288415

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Challenges in miRNA research in neurodegenerative diseases include identifying disease-specific miRNA signatures, understanding the mechanisms of miRNA loading into EVs, and elucidating the exact role of these miRNAs in disease progression.

    “Challenges include identifying disease-specific miRNA signatures, understanding the mechanisms of miRNA loading into EVs, and elucidating the exact role of these miRNAs in disease progression [174].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [174]

    The Neurodegenerative Diseases section (page unavailable) describes EV-miRNA signatures in Parkinson’s disease and ALS, supporting the claim’s focus on disease-associated signatures. It does not identify finding such signatures as an outstanding challenge, or state that miRNA loading mechanisms and the exact roles of miRNAs in disease progression remain to be elucidated. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 172 · Cited by 44

Research works printed but not linked: 157

  1. [1]Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7(1): 1535750. 30637094 PMC6322352
  2. [2]Yang D, Zhang W, Zhang H, et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics. 2020; 10(8): 3684– 3707. doi: 10.7150/thno.41580 32206116 PMC7069071 · DOI
  3. [3]Sims B, Gu L, Krendelchtchikov A, Matthews QL. Neural stem cell-derived exosomes mediate viral entry. Int J Nanomedicine. 2014; 9: 4893– 4897. doi: 10.2147/IJN.S70999 25364247 PMC4211904 · DOI
  4. [5]Sharma P, Schiapparelli L, Cline HT. Exosomes function in cell-cell communication during brain circuit development. Curr Opin Neurobiol. 2013; 23(6): 997– 1004. doi: 10.1016/j.conb.2013.08.005 23998929 PMC3830597 · DOI
  5. [6]Kalra H, Simpson RJ, Ji H, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012; 10(12): e1001450. doi: 10.1371/journal.pbio.1001450 23271954 PMC3525526 · DOI · Paper page
  6. [7]Bergsmedh A, Szeles A, Henriksson M, et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci U S A. 2001; 98(11): 6407– 6411. doi: 10.1073/pnas.101129998 11353826 PMC33481 · DOI · Paper page
  7. [8]Gregory CD, Dransfield I. Apoptotic tumor cell-derived extracellular vesicles as important regulators of the onco-regenerative niche. Front Immunol. 2018; 9: 1111. doi: 10.3389/fimmu.2018.01111 29875772 PMC5974173 · DOI
  8. [9]Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367(6478): eaau6977. doi: 10.1126/science.aau6977 32029601 PMC7717626 · DOI · Paper page
  9. [10]Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996; 183(3): 1161– 1172. doi: 10.1084/jem.183.3.1161 8642258 PMC2192324 · DOI · Paper page
  10. [11]Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3): 297– 303. doi: 10.1038/85438 11231627 · DOI
  11. [12]Hurley JH. ESCRTs are everywhere. EMBO J. 2015; 34(19): 2398– 2407. doi: 10.15252/embj.201592484 26311197 PMC4601661 · DOI
  12. [13]Zhen Y, Stenmark H. Cellular functions of Rab GTPases at a glance. J Cell Sci. 2015; 128(17): 3171– 3176. doi: 10.1242/jcs.166074 26272922 · DOI
  13. [14]Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010; 12(1): 19– 30. doi: 10.1038/ncb2000 19966785 · DOI
  14. [15]Gross JC, Chaudhary V, Bartscherer K, Boutros M. Active Wnt proteins are secreted on exosomes. Nat Cell Biol. 2012; 14(10): 1036– 1045. doi: 10.1038/ncb2574 22983114 · DOI
  15. [16]Verweij FJ, Bebelman MP, Jimenez CR, et al. Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling. J Cell Biol. 2018; 217(3): 1129– 1142. doi: 10.1083/jcb.201703206 29339438 PMC5839777 · DOI
  16. [17]Sedgwick AE, D’Souza-Schorey C. The biology of extracellular microvesicles. Traffic. 2018; 19(5): 319– 327. doi: 10.1111/tra.12558 29479795 PMC6922305 · DOI
  17. [18]Granger E, McNee G, Allan V, Woodman P. The role of the cytoskeleton and molecular motors in endosomal dynamics. Semin Cell Dev Biol. 2014; 31: 20– 29. doi: 10.1016/j.semcdb.2014.04.011 24727350 PMC4071412 · DOI
  18. [19]Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6): 654– 659. doi: 10.1038/ncb1596 17486113 · DOI · Paper page
  19. [20]Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006; 20(5): 847– 856. doi: 10.1038/sj.leu.2404132 16453000 · DOI
  20. [21]Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12): 1470– 1476. doi: 10.1038/ncb1800 19011622 PMC3423894 · DOI · Paper page
  21. [22]Tkach M, Kowal J, Zucchetti AE, et al. Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. EMBO J. 2017; 36(20): 3012– 3028. doi: 10.15252/embj.201696003 28923825 PMC5641679 · DOI
  22. [23]Cossetti C, Iraci N, Mercer TR, et al. Extracellular vesicles from neural stem cells transfer IFN-gamma via Ifngr1 to activate Stat1 signaling in target cells. Mol Cell. 2014; 56(2): 193– 204. doi: 10.1016/j.molcel.2014.08.020 25242146 PMC4578249 · DOI
  23. [24]Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3): 195– 208. doi: 10.1038/nri3622 24566916 PMC4350779 · DOI · Paper page
  24. [25]Stefanius K, Servage K, de Souza Santos M, et al. Human pancreatic cancer cell exosomes, but not human normal cell exosomes, act as an initiator in cell transformation. Elife. 2019; 8: e40226. doi: 10.7554/eLife.40226 31134894 PMC6538373 · DOI
  25. [26]Le MT, Hamar P, Guo C, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014; 124(12): 5109– 5128. doi: 10.1172/JCI75695 25401471 PMC4348969 · DOI
  26. [28]Ricklefs FL, Alayo Q, Krenzlin H, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018; 4(3): eaar2766. doi: 10.1126/sciadv.aar2766 29532035 PMC5842038 · DOI · Paper page
  27. [29]Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of extracellular vesicles: general methodologies and latest trends. Biomed Res Int. 2018; 2018: 8545347. doi: 10.1155/2018/8545347 29662902 PMC5831698 · DOI
  28. [30]Onodi Z, Pelyhe C, Terezia Nagy C, et al. Isolation of high-purity extracellular vesicles by the combination of iodixanol density gradient ultracentrifugation and bind-elute chromatography from blood plasma. Front Physiol. 2018; 9: 1479. doi: 10.3389/fphys.2018.01479 30405435 PMC6206048 · DOI
  29. [31]He L, Zhu D, Wang J, Wu X. A highly efficient method for isolating urinary exosomes. Int J Mol Med. 2019; 43(1): 83– 90. doi: 10.3892/ijmm.2018.3944 30365060 PMC6257847 · DOI
  30. [32]Patel GK, Khan MA, Zubair H, et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci Rep. 2019; 9(1): 5335. doi: 10.1038/s41598-019-41800-2 30926864 PMC6441044 · DOI
  31. [33]Taylor DD, Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 2015; 87: 3– 10. doi: 10.1016/j.ymeth.2015.02.019 25766927 · DOI
  32. [34]Gyorgy B, Modos K, Pallinger E, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood. 2011; 117(4): e39– e48. doi: 10.1182/blood-2010-09-307595 21041717 · DOI
  33. [35]Dragovic RA, Gardiner C, Brooks AS, et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine. 2011; 7(6): 780– 788. doi: 10.1016/j.nano.2011.04.003 21601655 PMC3280380 · DOI
  34. [36]Momen-Heravi F, Balaj L, Alian S, et al. Alternative methods for characterization of extracellular vesicles. Front Physiol. 2012; 3: 354. doi: 10.3389/fphys.2012.00354 22973237 PMC3435888 · DOI
  35. [37]Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017; 1008: 1– 46. 28815535
  36. [38]Conigliaro A, Costa V, Lo Dico A, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015; 14: 155. doi: 10.1186/s12943-015-0426-x 26272696 PMC4536801 · DOI
  37. [39]Liu Y, Zou R, Wang Z, Wen C, Zhang F, Lin F. Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and chondrocyte proliferation in osteoarthritis. Biochem J. 2018; 475(22): 3629– 3638. doi: 10.1042/BCJ20180675 30341166 · DOI
  38. [40]Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015; 25(8): 981– 984. doi: 10.1038/cr.2015.82 26138677 PMC4528056 · DOI
  39. [41]Wang Y, Liu J, Ma J, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019; 18(1): 116. doi: 10.1186/s12943-019-1041-z 31277663 PMC6610963 · DOI
  40. [42]Zhang X, Wang S, Wang H, et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019; 18(1): 20. doi: 10.1186/s12943-018-0935-5 30717751 PMC6360801 · DOI
  41. [43]Qian L, Yu S, Chen Z, Meng Z, Huang S, Wang P. The emerging role of circRNAs and their clinical significance in human cancers. Biochim Biophys Acta Rev Cancer. 2018; 1870(2): 247– 260. doi: 10.1016/j.bbcan.2018.06.002 29928954 · DOI
  42. [44]Zhang H, Zhu L, Bai M, et al. Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PRDM16 pathway. Int J Cancer. 2019; 144(10): 2501– 2515. doi: 10.1002/ijc.31977 30412280 · DOI
  43. [45]Tian L, Cao J, Jiao H, et al. CircRASSF2 promotes laryngeal squamous cell carcinoma progression by regulating the miR-302b-3p/IGF-1R axis. Clin Sci (Lond). 2019; 133(9): 1053– 1066. doi: 10.1042/CS20190110 30992382 · DOI
  44. [46]Li Z, Yanfang W, Li J, et al. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 2018; 432: 237– 250. doi: 10.1016/j.canlet.2018.04.035 29709702 · DOI
  45. [47]Li L, Li W, Chen N, et al. FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer. Clin Cancer Res. 2019; 25(4): 1302– 1317. doi: 10.1158/1078-0432.CCR-18-1447 30429198 · DOI
  46. [48]Batiz LF, Castro MA, Burgos PV, et al. Exosomes as novel regulators of adult neurogenic niches. Front Cell Neurosci. 2015; 9: 501. doi: 10.3389/fncel.2015.00501 26834560 PMC4717294 · DOI
  47. [49]Zhao C, Sun G, Li S, Shi Y. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nat Struct Mol Biol. 2009; 16(4): 365– 371. doi: 10.1038/nsmb.1576 19330006 PMC2667220 · DOI · Paper page
  48. [50]Zhao C, Sun G, Li S, et al. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc Natl Acad Sci U S A. 2010; 107(5): 1876– 1881. doi: 10.1073/pnas.0908750107 20133835 PMC2836616 · DOI
  49. [51]Sharma P, Mesci P, Carromeu C, et al. Exosomes regulate neurogenesis and circuit assembly. Proc Natl Acad Sci U S A. 2019; 116(32): 16086– 16094. doi: 10.1073/pnas.1902513116 31320591 PMC6689941 · DOI
  50. [52]Holm MM, Kaiser J, Schwab ME. Extracellular vesicles: multimodal envoys in neural maintenance and repair. Trends Neurosci. 2018; 41(6): 360– 372. doi: 10.1016/j.tins.2018.03.006 29605090 · DOI
  51. [53]Mateos-Aparicio P, Rodriguez-Moreno A. Calcium dynamics and synaptic plasticity. Adv Exp Med Biol. 2020; 1131(965–984). 31646541
  52. [54]Lachenal G, Pernet-Gallay K, Chivet M, et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci. 2011; 46(2): 409– 418. doi: 10.1016/j.mcn.2010.11.004 21111824 · DOI
  53. [55]Chivet M, Javalet C, Hemming F, et al. Exosomes as a novel way of interneuronal communication. Biochem Soc Trans. 2013; 41(1): 241– 244. doi: 10.1042/BST20120266 23356290 · DOI
  54. [56]Korkut C, Ataman B, Ramachandran P, et al. Trans-synaptic transmission of vesicular Wnt signals through Evi/Wntless. Cell. 2009; 139(2): 393– 404. doi: 10.1016/j.cell.2009.07.051 19837038 PMC2785045 · DOI · Paper page
  55. [57]Koles K, Nunnari J, Korkut C, et al. Mechanism of evenness interrupted (Evi)-exosome release at synaptic boutons. J Biol Chem. 2012; 287(20): 16820– 16834. doi: 10.1074/jbc.M112.342667 22437826 PMC3351299 · DOI
  56. [58]Ashley J, Cordy B, Lucia D, Fradkin LG, Budnik V, Thomson T. Retrovirus-like Gag protein Arc1 binds RNA and traffics across synaptic boutons. Cell. 2018; 172(1–2): 262– 274 e211. doi: 10.1016/j.cell.2017.12.022 29328915 PMC5793882 · DOI · Paper page
  57. [59]Bahrini I, Song JH, Diez D, Hanayama R. Neuronal exosomes facilitate synaptic pruning by up-regulating complement factors in microglia. Sci Rep. 2015; 5: 7989. doi: 10.1038/srep07989 25612542 PMC4303875 · DOI
  58. [60]Falker C, Hartmann A, Guett I, et al. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity. J Neurochem. 2016; 137(1): 88– 100. doi: 10.1111/jnc.13514 26710111 · DOI
  59. [61]Yuyama K, Sun H, Usuki S, et al. A potential function for neuronal exosomes: sequestering intracerebral amyloid-beta peptide. FEBS Lett. 2015; 589(1): 84– 88. doi: 10.1016/j.febslet.2014.11.027 25436414 · DOI
  60. [62]Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015; 18(11): 1584– 1593. doi: 10.1038/nn.4132 26436904 PMC4694577 · DOI · Paper page
  61. [63]Stuendl A, Kunadt M, Kruse N, et al. Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain. 2016; 139(2): 481– 494. doi: 10.1093/brain/awv346 26647156 PMC4805087 · DOI · Paper page
  62. [64]Basso M, Pozzi S, Tortarolo M, et al. Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J Biol Chem. 2013; 288(22): 15699– 15711. doi: 10.1074/jbc.M112.425066 23592792 PMC3668729 · DOI
  63. [65]Iguchi Y, Eid L, Parent M, et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016; 139(12): 3187– 3201. doi: 10.1093/brain/aww237 27679482 PMC5840881 · DOI · Paper page
  64. [66]Niu M, Li Y, Li G, et al. A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression. Eur J Neurol. 2020; 27(6): 967– 974. doi: 10.1111/ene.14208 32150777 · DOI · Paper page
  65. [67]Zhao ZH, Chen ZT, Zhou RL, Zhang X, Ye QY, Wang YZ. Increased DJ-1 and alpha-synuclein in plasma neural-derived exosomes as potential markers for parkinson’s disease. Front Aging Neurosci. 2018; 10: 438. doi: 10.3389/fnagi.2018.00438 30692923 PMC6339871 · DOI
  66. [68]Jiang C, Hopfner F, Katsikoudi A, et al. Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020; 91(7): 720– 729. doi: 10.1136/jnnp-2019-322588 32273329 PMC7361010 · DOI
  67. [69]Cao Z, Wu Y, Liu G, et al. alpha-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease. Neurosci Lett. 2019; 696: 114– 120. doi: 10.1016/j.neulet.2018.12.030 30579996 · DOI
  68. [70]Si X, Tian J, Chen Y, Yan Y, Pu J, Zhang B. Central nervous system-derived exosomal alpha-synuclein in serum may be a biomarker in parkinson’s disease. Neuroscience. 2019; 413: 308– 316. doi: 10.1016/j.neuroscience.2019.05.015 31102760 · DOI
  69. [71]Shi M, Liu C, Cook TJ, et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014; 128(5): 639– 650. doi: 10.1007/s00401-014-1314-y 24997849 PMC4201967 · DOI · Paper page
  70. [72]Fraser KB, Rawlins AB, Clark RG, et al. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson’s disease. Mov Disord. 2016; 31(10): 1543– 1550. doi: 10.1002/mds.26686 27297049 PMC5053851 · DOI
  71. [73]Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015; 6(35): 37043– 37053. doi: 10.18632/oncotarget.6158 26497684 PMC4741914 · DOI · Paper page
  72. [74]Wang Q, Han CL, Wang KL, et al. Integrated analysis of exosomal lncRNA and mRNA expression profiles reveals the involvement of lnc-MKRN2-42:1 in the pathogenesis of Parkinson’s disease. CNS Neurosci Ther. 2020; 26(5): 527– 537. 31814304 PMC7163584
  73. [76]Chen HX, Liang FC, Gu P, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson’s disease model by inducing autophagy. Cell Death Dis. 2020; 11(4): 288. doi: 10.1038/s41419-020-2473-5 32341347 PMC7184757 · DOI · Paper page
  74. [77]Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015; 207: 18– 30. doi: 10.1016/j.jconrel.2015.03.033 25836593 PMC4430381 · DOI · Paper page
  75. [78]Kojima R, Bojar D, Rizzi G, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun. 2018; 9(1): 1305. doi: 10.1038/s41467-018-03733-8 29610454 PMC5880805 · DOI · Paper page
  76. [79]Cooper JM, Wiklander PB, Nordin JZ, et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord. 2014; 29(12): 1476– 1485. doi: 10.1002/mds.25978 25112864 PMC4204174 · DOI
  77. [80]Izco M, Blesa J, Schleef M, et al. Systemic exosomal delivery of shRNA minicircles prevents parkinsonian pathology. Mol Ther. 2019; 27(12): 2111– 2122. doi: 10.1016/j.ymthe.2019.08.010 31501034 PMC6904801 · DOI
  78. [82]Sun R, Wang H, Shi Y, Sun Z, Jiang H, Zhang J. Changes in the morphology, number, and pathological protein levels of plasma exosomes may help diagnose alzheimer’s disease. J Alzheimers Dis. 2020; 73(3): 909– 917. doi: 10.3233/JAD-190497 31884461 · DOI
  79. [83]Nam E, Lee YB, Moon C, Chang KA. Serum tau proteins as potential biomarkers for the assessment of alzheimer’s disease progression. Int J Mol Sci. 2020; 21(14): 5007. doi: 10.3390/ijms21145007 PMC7404390 32679907 · DOI
  80. [85]Hamlett ED, LaRosa A, Mufson EJ, Fortea J, Ledreux A, Granholm AC. Exosome release and cargo in Down syndrome. Dev Neurobiol. 2019; 79(7): 639– 655. doi: 10.1002/dneu.22712 31347291 PMC7388580 · DOI
  81. [86]Jain G, Stuendl A, Rao P, et al. A combined miRNA-piRNA signature to detect Alzheimer’s disease. Transl Psychiatry. 2019; 9(1): 250. doi: 10.1038/s41398-019-0579-2 31591382 PMC6779890 · DOI · Paper page
  82. [87]Yang L, Zhai Y, Hao Y, Zhu Z, Cheng G. The regulatory functionality of exosomes derived from hUMSCs in 3D culture for alzheimer’s disease therapy. Small. 2020; 16(3): e1906273. doi: 10.1002/smll.201906273 31840420 · DOI
  83. [88]Nakano M, Kubota K, Kobayashi E, et al. Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer’s disease model by increasing the expression of microRNA-146a in hippocampus. Sci Rep. 2020; 10(1): 10772. doi: 10.1038/s41598-020-67460-1 32612165 PMC7330036 · DOI
  84. [91]Hayashi N, Doi H, Kurata Y, et al. Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurosci Res. 2019; S0168–S0102(19):. 30487 31669371
  85. [92]Thompson AG, Gray E, Mager I, et al. CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. Clin Proteomics. 2020; 17: 31. doi: 10.1186/s12014-020-09294-7 32821252 PMC7433176 · DOI
  86. [93]Katsu M, Hama Y, Utsumi J, et al. MicroRNA expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci Lett. 2019; 708: 134176. doi: 10.1016/j.neulet.2019.03.048 31173847 · DOI
  87. [94]Saucier D, Wajnberg G, Roy J, et al. Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res. 2019; 1708: 100– 108. doi: 10.1016/j.brainres.2018.12.016 30552897 · DOI
  88. [95]Lee M, Ban JJ, Kim KY, et al. Adipose-derived stem cell exosomes alleviate pathology of amyotrophic lateral sclerosis in vitro. Biochem Biophys Res Commun. 2016; 479(3): 434– 439. doi: 10.1016/j.bbrc.2016.09.069 27641665 · DOI
  89. [96]Bonafede R, Brandi J, Manfredi M, et al. The anti-apoptotic effect of ASC-exosomes in an in vitro ALS model and their proteomic analysis. Cells. 2019; 8(9): 1087. doi: 10.3390/cells8091087 PMC6770878 31540100 · DOI
  90. [97]Bonafede R, Turano E, Scambi I, et al. ASC-exosomes ameliorate the disease progression in SOD1(G93A) murine model underlining their potential therapeutic use in human ALS. Int J Mol Sci. 2020; 21(10): 3651. doi: 10.3390/ijms21103651 PMC7279464 32455791 · DOI · Paper page
  91. [98]Wang G, Dinkins M, He Q, et al. Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). J Biol Chem. 2012; 287(25): 21384– 21395. doi: 10.1074/jbc.M112.340513 22532571 PMC3375560 · DOI
  92. [99]Ubhi K, Peng K, Lessig S, et al. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neurosci Lett. 2010; 485(3): 222– 227. doi: 10.1016/j.neulet.2010.09.016 20849919 PMC2987680 · DOI
  93. [100]Colom-Cadena M, Grau-Rivera O, Planellas L, et al. Regional overlap of pathologies in lewy body disorders. J Neuropathol Exp Neurol. 2017; 76(3): 216– 224. doi: 10.1093/jnen/nlx002 28395086 · DOI
  94. [101]Gamez-Valero A, Campdelacreu J, Rene R, Beyer K, Borras FE. Comprehensive proteomic profiling of plasma-derived Extracellular Vesicles from dementia with Lewy Bodies patients. Sci Rep. 2019; 9(1): 13282. doi: 10.1038/s41598-019-49668-y 31527695 PMC6746766 · DOI
  95. [102]Gamez-Valero A, Campdelacreu J, Vilas D, et al. Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer’s disease and dementia with Lewy bodies. Transl Neurodegener. 2019; 8: 31. doi: 10.1186/s40035-019-0169-5 31592314 PMC6775659 · DOI
  96. [104]Ji Q, Ji Y, Peng J, et al. Increased brain-specific MiR-9 and MiR-124 in the serum exosomes of acute ischemic stroke patients. PLoS One. 2016; 11(9): e0163645. doi: 10.1371/journal.pone.0163645 27661079 PMC5035015 · DOI
  97. [105]Kerr N, Garcia-Contreras M, Abbassi S, et al. Inflammasome proteins in serum and serum-derived extracellular vesicles as biomarkers of stroke. Front Mol Neurosci. 2018; 11: 309. doi: 10.3389/fnmol.2018.00309 30233311 PMC6131639 · DOI
  98. [106]Gui Y, Xu Z, Jin T, et al. Using extracellular circulating microRNAs to classify the etiological subtypes of ischemic stroke. Transl Stroke Res. 2019; 10(4): 352– 361. doi: 10.1007/s12975-018-0659-2 30178428 · DOI
  99. [107]Kalani MYS, Alsop E, Meechoovet B, et al. Extracellular microRNAs in blood differentiate between ischaemic and haemorrhagic stroke subtypes. J Extracell Vesicles. 2020; 9(1): 1713540. doi: 10.1080/20013078.2020.1713540 32128071 PMC7034450 · DOI
  100. [108]Chi NF, Chiou HY, Chou SY, et al. Hyperglycemia-related FAS gene and hsa-let-7b-5p as markers of poor outcomes for ischaemic stroke. Eur J Neurol. 2020; 27(8): 1647– 1655. doi: 10.1111/ene.14288 32352616 · DOI
  101. [109]Doeppner TR, Herz J, Gorgens A, et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med. 2015; 4(10): 1131– 1143. doi: 10.5966/sctm.2015-0078 26339036 PMC4572905 · DOI
  102. [110]Otero-Ortega L, Laso-Garcia F, Gomez-de Frutos MD, et al. White matter repair after extracellular vesicles administration in an experimental animal model of subcortical stroke. Sci Rep. 2017; 7: 44433. doi: 10.1038/srep44433 28300134 PMC5353554 · DOI
  103. [111]Moon GJ, Sung JH, Kim DH, et al. Application of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Stroke: biodistribution and MicroRNA Study. Transl Stroke Res. 2019; 10(5): 509– 521. doi: 10.1007/s12975-018-0668-1 30341718 · DOI · Paper page
  104. [112]Webb RL, Kaiser EE, Jurgielewicz BJ, et al. Human neural stem cell extracellular vesicles improve recovery in a porcine model of ischemic stroke. Stroke. 2018; 49(5): 1248– 1256. doi: 10.1161/STROKEAHA.117.020353 29650593 PMC5916046 · DOI
  105. [113]Zheng X, Zhang L, Kuang Y, et al. Extracellular vesicles derived from neural progenitor cells–a preclinical evaluation for stroke treatment in mice. Transl Stroke Res. 2020; 12: 185– 203. doi: 10.1007/s12975-020-00814-z 32361827 PMC7803677 · DOI
  106. [114]Lapchak PA, Boitano PD, de Couto G, Marban E. Intravenous xenogeneic human cardiosphere-derived cell extracellular vesicles (exosomes) improves behavioral function in small-clot embolized rabbits. Exp Neurol. 2018; 307: 109– 117. doi: 10.1016/j.expneurol.2018.06.007 29908146 · DOI
  107. [115]Yang J, Zhao Y, Zhang L, et al. RIPK3/MLKL-mediated neuronal necroptosis modulates the M1/M2 polarization of microglia/macrophages in the ischemic cortex. Cereb Cortex. 2018; 28(7): 2622– 2635. doi: 10.1093/cercor/bhy089 29746630 PMC5998990 · DOI
  108. [116]Ghosh M, Xu Y, Pearse DD. Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines. J Neuroinflammation. 2016; 13: 9. doi: 10.1186/s12974-015-0463-9 26757726 PMC4711034 · DOI
  109. [117]Brifault C, Gras M, Liot D, May V, Vaudry D, Wurtz O. Delayed pituitary adenylate cyclase-activating polypeptide delivery after brain stroke improves functional recovery by inducing m2 microglia/macrophage polarization. Stroke. 2015; 46(2): 520– 528. doi: 10.1161/STROKEAHA.114.006864 25550371 · DOI
  110. [118]Zheng Y, He R, Wang P, Shi Y, Zhao L, Liang J. Exosomes from LPS-stimulated macrophages induce neuroprotection and functional improvement after ischemic stroke by modulating microglial polarization. Biomater Sci. 2019; 7(5): 2037– 2049. doi: 10.1039/C8BM01449C 30843911 · DOI
  111. [120]Tian T, Zhang HX, He CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018; 150: 137– 149. doi: 10.1016/j.biomaterials.2017.10.012 29040874 · DOI · Paper page
  112. [122]Li F, Zhao L, Shi Y, Liang J. Edaravone-loaded macrophage-derived exosomes enhance neuroprotection in the rat permanent middle cerebral artery occlusion model of stroke. Mol Pharm. 2020; 17(9): 3192– 3201. doi: 10.1021/acs.molpharmaceut.0c00245 32786956 · DOI
  113. [123]Xin H, Katakowski M, Wang F, et al. MicroRNA cluster miR-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. Stroke. 2017; 48(3): 747– 753. doi: 10.1161/STROKEAHA.116.015204 28232590 PMC5330787 · DOI
  114. [124]Zhang H, Wu J, Wu J, et al. Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice. J Nanobiotechnology. 2019; 17(1): 29. doi: 10.1186/s12951-019-0461-7 30782171 PMC6379944 · DOI
  115. [126]Yang L, Han B, Zhang Z, et al. Extracellular vesicle-mediated delivery of circular RNA SCMH1 promotes functional recovery in rodent and nonhuman primate ischemic stroke models. Circulation. 2020; 142(6): 556– 574. doi: 10.1161/CIRCULATIONAHA.120.045765 32441115 · DOI · Paper page
  116. [127]Mutch CA, Talbott JF, Gean A. Imaging evaluation of acute traumatic brain injury. Neurosurg Clin N Am. 2016; 27(4): 409– 439. doi: 10.1016/j.nec.2016.05.011 27637393 PMC5027071 · DOI
  117. [128]Manek R, Moghieb A, Yang Z, et al. Protein biomarkers and neuroproteomics characterization of microvesicles/exosomes from human cerebrospinal fluid following traumatic brain injury. Mol Neurobiol. 2018; 55(7): 6112– 6128. doi: 10.1007/s12035-017-0821-y 29188495 PMC6359938 · DOI
  118. [129]Cheng Y, Pereira M, Raukar N, et al. Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles. J Cell Physiol. 2019; 234(8): 14377– 14388. doi: 10.1002/jcp.28139 30644102 PMC6478516 · DOI
  119. [130]Wang P, Ma H, Zhang Y, et al. Plasma exosome-derived microRNAs as novel biomarkers of traumatic brain injury in rats. Int J Med Sci. 2020; 17(4): 437– 448. doi: 10.7150/ijms.39667 32174774 PMC7053301 · DOI
  120. [131]Williams AM, Bhatti UF, Brown JF, et al. Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020; 88(2): 207– 218. doi: 10.1097/TA.0000000000002563 31804413 · DOI
  121. [132]Williams AM, Wu Z, Bhatti UF, et al. Early single-dose exosome treatment improves neurologic outcomes in a 7-day swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020; 89(2): 388– 396. doi: 10.1097/TA.0000000000002698 32218019 · DOI
  122. [133]Kim DK, Nishida H, An SY, Shetty AK, Bartosh TJ, Prockop DJ. Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc Natl Acad Sci U S A. 2016; 113(1): 170– 175. doi: 10.1073/pnas.1522297113 26699510 PMC4711859 · DOI
  123. [135]Li Y, Yang YY, Ren JL, Xu F, Chen FM, Li A. Exosomes secreted by stem cells from human exfoliated deciduous teeth contribute to functional recovery after traumatic brain injury by shifting microglia M1/M2 polarization in rats. Stem Cell Res Ther. 2017; 8(1): 198. doi: 10.1186/s13287-017-0648-5 28962585 PMC5622448 · DOI
  124. [136]Ding SQ, Chen YQ, Chen J, et al. Serum exosomal microRNA transcriptome profiling in subacute spinal cord injured rats. Genomics. 2020; 112(2): 2092– 2105. doi: 10.1016/j.ygeno.2019.12.003 31830526 · DOI
  125. [137]Romanelli P, Bieler L, Scharler C, et al. Extracellular vesicles can deliver anti-inflammatory and anti-scarring activities of mesenchymal stromal cells after spinal cord injury. Front Neurol. 2019; 10: 1225. doi: 10.3389/fneur.2019.01225 31849808 PMC6896947 · DOI
  126. [138]Goncalves MB, Malmqvist T, Clarke E, et al. Neuronal RARbeta signaling modulates PTEN activity directly in neurons and via exosome transfer in astrocytes to prevent glial scar formation and induce spinal cord regeneration. J Neurosci. 2015; 35(47): 15731– 15745. doi: 10.1523/JNEUROSCI.1339-15.2015 26609164 PMC4659830 · DOI
  127. [139]Guo S, Perets N, Betzer O, et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury. ACS Nano. 2019; 13(9): 10015– 10028. doi: 10.1021/acsnano.9b01892 31454225 · DOI · Paper page
  128. [140]Wang Z, Song Y, Han X, Qu P, Wang W. Long noncoding RNA PTENP1 affects the recovery of spinal cord injury by regulating the expression of miR-19b and miR-21. J Cell Physiol. 2020; 235(4): 3634– 3645. doi: 10.1002/jcp.29253 31583718 PMC13482677 · DOI
  129. [141]Kang J, Li Z, Zhi Z, Wang S, Xu G. MiR-21 derived from the exosomes of MSCs regulates the death and differentiation of neurons in patients with spinal cord injury. Gene Ther. 2019; 26(12): 491– 503. doi: 10.1038/s41434-019-0101-8 31570818 · DOI
  130. [142]Xu G, Ao R, Zhi Z, Jia J, Yu B. miR-21 and miR-19b delivered by hMSC-derived EVs regulate the apoptosis and differentiation of neurons in patients with spinal cord injury. J Cell Physiol. 2019; 234(7): 10205– 10217. doi: 10.1002/jcp.27690 30387159 · DOI
  131. [143]He J, Ren M, Li H, Yang L, Wang X, Yang Q. Exosomal circular RNA as a biomarker platform for the early diagnosis of immune-mediated demyelinating disease. Front Genet. 2019; 10: 860. doi: 10.3389/fgene.2019.00860 31611906 PMC6777646 · DOI
  132. [144]Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014; 122: 15– 58. 24507512
  133. [145]Ebrahimkhani S, Vafaee F, Young PE, et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep. 2017; 7(1): 14293. doi: 10.1038/s41598-017-14301-3 29084979 PMC5662562 · DOI
  134. [146]Selmaj I, Cichalewska M, Namiecinska M, et al. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol. 2017; 81(5): 703– 717. doi: 10.1002/ana.24931 28411393 · DOI
  135. [147]Manna I, Iaccino E, Dattilo V, et al. Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. FASEB J. 2018; 32(8): 4241– 4246. doi: 10.1096/fj.201701533R 29505299 · DOI
  136. [148]Ebrahimkhani S, Beadnall HN, Wang C, et al. Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment. Mol Neurobiol. 2020; 57(2): 1245– 1258. doi: 10.1007/s12035-019-01792-6 31721043 · DOI
  137. [149]Chen C, Wu Y, Li M, et al. Different exosomal microRNA profile in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders. Front Immunol. 2020; 11: 1064. doi: 10.3389/fimmu.2020.01064 32547558 PMC7274160 · DOI
  138. [151]Clark K, Zhang S, Barthe S, et al. Placental mesenchymal stem cell-derived extracellular vesicles promote myelin regeneration in an animal model of multiple sclerosis. Cells. 2019; 8(12): 1497. doi: 10.3390/cells8121497 PMC6952942 31771176 · DOI
  139. [152]Hosseini Shamili F, Alibolandi M, Rafatpanah H, et al. Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score. J Control Release. 2019; 299: 149– 164. doi: 10.1016/j.jconrel.2019.02.032 30807806 · DOI
  140. [153]Hyun KA, Kim J, Gwak H, Jung HI. Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics. Analyst. 2016; 141(2): 382– 392. doi: 10.1039/C5AN01762A 26588824 · DOI
  141. [154]Figueroa JM, Skog J, Akers J, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017; 19(11): 1494– 1502. doi: 10.1093/neuonc/nox085 28453784 PMC5737576 · DOI
  142. [155]Akers JC, Ramakrishnan V, Kim R, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol. 2015; 123(2): 205– 216. doi: 10.1007/s11060-015-1784-3 25903655 PMC4459648 · DOI
  143. [156]Lan F, Qing Q, Pan Q, Hu M, Yu H, Yue X. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 2018; 41(1): 25– 33. doi: 10.1007/s13402-017-0355-3 29076027 PMC12995224 · DOI
  144. [157]Ricklefs FL, Maire CL, Matschke J, et al. FASN is a biomarker enriched in malignant glioma-derived extracellular vesicles. Int J Mol Sci. 2020; 21(6): 1931. doi: 10.3390/ijms21061931 PMC7139767 32178271 · DOI
  145. [158]Garcia-Romero N, Carrion-Navarro J, Esteban-Rubio S, et al. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget. 2017; 8(1): 1416– 1428. doi: 10.18632/oncotarget.13635 27902458 PMC5352065 · DOI
  146. [159]Indira Chandran V, Welinder C, Mansson AS, et al. Ultrasensitive immunoprofiling of plasma extracellular vesicles identifies syndecan-1 as a potential tool for minimally invasive diagnosis of glioma. Clin Cancer Res. 2019; 25(10): 3115– 3127. 30679164
  147. [160]Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health and disease. Platelets. 2017; 28(3): 214– 221. doi: 10.1080/09537104.2016.1265924 28102737 · DOI
  148. [161]Al-Mufti F, Claassen J. Neurocritical care: status epilepticus review. Crit Care Clin. 2014; 30(4): 751– 764. doi: 10.1016/j.ccc.2014.06.006 25257739 · DOI
  149. [162]Raoof R, Jimenez-Mateos EM, Bauer S, et al. Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. Sci Rep. 2017; 7(1): 3328. doi: 10.1038/s41598-017-02969-6 28607431 PMC5468228 · DOI
  150. [163]Yan S, Zhang H, Xie W, et al. Altered microRNA profiles in plasma exosomes from mesial temporal lobe epilepsy with hippocampal sclerosis. Oncotarget. 2017; 8(3): 4136– 4146. doi: 10.18632/oncotarget.13744 27926529 PMC5354818 · DOI
  151. [164]Lin Z, Gu Y, Zhou R, et al. Serum exosomal proteins F9 and TSP-1 as potential diagnostic biomarkers for newly diagnosed epilepsy. Front Neurosci. 2020; 14: 737. doi: 10.3389/fnins.2020.00737 32848539 PMC7417627 · DOI
  152. [165]Upadhya D, Shetty AK. Promise of extracellular vesicles for diagnosis and treatment of epilepsy. Epilepsy Behav. 2019; 106499. doi: 10.1016/j.yebeh.2019.106499 31636006 PMC7165061 · DOI
  153. [166]Costa-Ferro ZS, Souza BS, Leal MM, et al. Transplantation of bone marrow mononuclear cells decreases seizure incidence, mitigates neuronal loss and modulates pro-inflammatory cytokine production in epileptic rats. Neurobiol Dis. 2012; 46(2): 302– 313. doi: 10.1016/j.nbd.2011.12.001 22198377 · DOI
  154. [167]Long Q, Upadhya D, Hattiangady B, et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci U S A. 2017; 114(17): E3536– E3545. doi: 10.1073/pnas.1703920114 28396435 PMC5410779 · DOI
  155. [168]Cao XY, Lu JM, Zhao ZQ, et al. MicroRNA biomarkers of Parkinson’s disease in serum exosome-like microvesicles. Neurosci Lett. 2017; 644: 94– 99. doi: 10.1016/j.neulet.2017.02.045 28223160 · DOI
  156. [169]Yao YF, Qu MW, Li GC, Zhang FB, Rui HC. Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2018; 22(16): 5278– 5283. doi: 10.26355/eurrev_201808_15727 30178852 · DOI
  157. [170]Barbagallo C, Mostile G, Baglieri G, et al. Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell Mol Neurobiol. 2020; 40(4): 531– 546. doi: 10.1007/s10571-019-00751-y 31691877 PMC11448951 · DOI

Authors
Jin, T., Gu, J., Li, Z., Xu, Z., & Gui, Y.
Affiliations
  • Sir Run Run Shaw Hospital (CN)
  • Washington University in St. Louis (US)
Corresponding author
Gui, Yaxing
ORCID
Venue
Clinical Interventions in Aging
Publisher
Informa UK Limited
Published
2021-02
Volume
Volume 16
Pages
257-274
ISSN
  • 1176-9092 (ISSN-L)
  • 1178-1998
DOI
10.2147/cia.s288415
PMC
PMC7882422
OpenAlex
W3126653531
Cited by
44
References
172
Citations by year
2026: 4 · 2025: 3 · 2024: 11 · 2023: 11 · 2022: 14 · 2021: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Interventions in Aging (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, other-oa)
Funders
  • National Natural Science Foundation of China (81401038)
  • Natural Science Foundation of Zhejiang Province (LY19H090018)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
Keywords
extracellular vesicles, central nervous system disorders, neurodegenerative diseases, cerebrovascular disease, traumatic brain injury, brain tumors, neuroinflammation, neuroprotection, protein aggregate clearance, biomarkers, drug carriers, blood-brain barrier, synaptic plasticity, myelination
MeSH terms
Extracellular Vesicles, Blood-Brain Barrier, Brain, Central Nervous System Diseases, Humans, Biomarkers, Drug Delivery Systems, Neurodegenerative Diseases, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review